Equities Analysts Offer Predictions for AKRO FY2029 Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Equities research analysts at HC Wainwright issued their FY2029 EPS estimates for Akero Therapeutics in a report released on Monday, January 27th. HC Wainwright analyst E. Arce anticipates that the company will earn $5.58 per share for the year. HC Wainwright has a “Buy” rating and a $72.00 price objective on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.96) per share.

Akero Therapeutics (NASDAQ:AKRO) last posted its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.15).

A number of other equities analysts have also issued reports on AKRO. Citigroup raised their price target on Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday. Canaccord Genuity Group upped their price target on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research note on Tuesday. Morgan Stanley raised their price objective on shares of Akero Therapeutics from $46.00 to $96.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Bank of America raised Akero Therapeutics from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $35.00 to $63.00 in a research note on Thursday. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $66.29.

Akero Therapeutics Price Performance

AKRO stock opened at $55.36 on Wednesday. Akero Therapeutics has a twelve month low of $15.32 and a twelve month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05. The company has a market capitalization of $3.86 billion, a P/E ratio of -14.76 and a beta of -0.19. The business has a 50 day simple moving average of $29.78 and a 200-day simple moving average of $28.69.

Insider Activity at Akero Therapeutics

In related news, insider Catriona Yale sold 9,061 shares of the business’s stock in a transaction that occurred on Friday, November 15th. The shares were sold at an average price of $27.73, for a total value of $251,261.53. Following the completion of the sale, the insider now directly owns 74,158 shares in the company, valued at approximately $2,056,401.34. The trade was a 10.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Andrew Cheng sold 25,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $32.09, for a total value of $802,250.00. Following the sale, the chief executive officer now owns 605,417 shares of the company’s stock, valued at approximately $19,427,831.53. The trade was a 3.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 149,303 shares of company stock valued at $6,206,412. 7.94% of the stock is owned by insiders.

Institutional Investors Weigh In On Akero Therapeutics

Several large investors have recently made changes to their positions in AKRO. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Akero Therapeutics by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,511 shares of the company’s stock worth $71,000 after buying an additional 446 shares in the last quarter. Eastern Bank bought a new stake in Akero Therapeutics during the third quarter valued at $100,000. Summit Financial Wealth Advisors LLC bought a new stake in shares of Akero Therapeutics during the 3rd quarter valued at about $205,000. Victory Capital Management Inc. bought a new position in shares of Akero Therapeutics during the third quarter valued at approximately $211,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Akero Therapeutics during the 3rd quarter worth approximately $265,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.